Bridging Strategies to Allogeneic Transplant for Older AML Patients

Cancers
Judith HeckerMareike Verbeek

Abstract

Treatment options for older patients with intermediate or high-risk acute myeloid leukemia (AML) remain unsatisfactory. Allogeneic stem cell transplantation, the treatment of choice for the majority of younger AML patients, has been hampered in elderly patients by higher treatment related mortality, comorbidities and lack of a suitable donor. With the higher availability of suitable donors as well as of reduced intensity conditioning regimens, novel low intensity treatments prior to transplantation and optimized supportive care, the number of older AML patients being successfully transplanted is steadily increasing. Against this background, we review current treatment strategies for older AML patients planned for allogeneic stem cell transplantation based on clinical trial data, discussing differences between approaches with advantages and pitfalls of each. We summarize pre-treatment considerations that need to be taken into account in this highly heterogeneous older population. Finally, we offer an outlook on areas of ongoing clinical research, including novel immunotherapeutic approaches that may improve access to curative therapies for a larger number of older AML patients.

References

Feb 4, 2006·Blood·Frederick R AppelbaumStephen H Petersdorf
May 10, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Elihu Estey
Aug 29, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mohamed L SorrorRainer Storb
Sep 4, 2008·American Journal of Hematology·Celalettin UstunAnand Jillella
Mar 18, 2009·British Journal of Haematology·Alan K BurnettUNKNOWN United Kingdom National Cancer Research Institute Haematological Oncology Study Group
Jul 31, 2009·Cancer·Alois GratwohlUNKNOWN European Group for Blood and Marrow Transplantation and the European Leukemia Net
Sep 25, 2009·The New England Journal of Medicine·Bob LöwenbergUNKNOWN Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group
Jan 16, 2010·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·John KorethVincent T Ho
Mar 10, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Brian L McCluneSergio Giralt
Apr 7, 2010·Proceedings of the National Academy of Sciences of the United States of America·William BlumGuido Marcucci
Nov 26, 2010·The New England Journal of Medicine·Ted A GooleyGeorge B McDonald
Mar 18, 2011·The New England Journal of Medicine·Bob LöwenbergUNKNOWN Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) Collab
May 25, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Markus SchaichGerhard Ehninger
Jun 28, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Sherif S FaragUNKNOWN Acute Leukemia Committee of the Center for International Blood and Marrow Transplant Research and Cancer and Leukemia Group
Jul 26, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Patrice ChevallierMohamad Mohty
Jan 19, 2012·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Aaron T GerdsBart L Scott
Sep 19, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Krzysztof MrózekClara D Bloomfield
May 3, 2013·The New England Journal of Medicine·UNKNOWN Cancer Genome Atlas Research NetworkGreg Eley
Oct 3, 2013·Expert Review of Hematology·Mohamed L Sorror, Frederick R Appelbaum

❮ Previous
Next ❯

Methods Mentioned

BETA
MDS

Clinical Trials Mentioned

NCT00766779
NCT02993523
NCT03069352
NCT02502968

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Related Papers

Bone Marrow Transplantation
S G PapageorgiouP D Kottaridis
International Journal of Hematologic Oncology
Yazeed Sawalha, Anjali S Advani
[Rinshō ketsueki] The Japanese journal of clinical hematology
Ken Ishiyama
Expert Review of Anticancer Therapy
Kim KleinGertjan J L Kaspers
Clinical Medicine Insights. Oncology
Tara L Lin, M Yair Levy
© 2022 Meta ULC. All rights reserved